NCT06829199 2026-02-19
MK-5890-003
Merck Sharp & Dohme LLC
Phase 2 Withdrawn
Clinical Trials
4 trialsNCT06144944 2026-01-30
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Active not recruiting
NCT04290793 2026-01-07
Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2/3 Active not recruiting
NCT04872985 2026-01-06
Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Active not recruiting